Also written as Yorvipath
Palopegteriparatide is a long-acting PTH prodrug. It is filed in this library under bones & muscles, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA. It is also written as Yorvipath.
Regulatory status
Palopegteriparatide has an FDA-approved product on the U.S. market, marketed as Yorvipath.
The current label is held by Ascendis Pharma, Endocrinology, Inc.
The evidence
One source on Palopegteriparatide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.
Nearby
A 60-second questionnaire, reviewed by a U.S.-licensed physician.
Find my protocolEducational reference only. This page explains what has been published about Palopegteriparatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides